Search results
Added:
3 years ago
Abstract
Heart failure with preserved left ventricular ejection fraction (HF-PEF), sometimes named diastolic heart failure, is a common condition most frequently seen in the elderly and is associated with arterial hypertension and left ventricular (LV) hypertrophy. Symptoms are attributed to a stiff left ventricle with compensatory elevation of filling pressure and reduced ability to increase…
View more
Added:
3 years ago
Abstract
The assessment of left ventricular ejection fraction is a key clinical investigation guiding the diagnosis, management and prognosis of cardiology patients. Echocardiography is an inexpensive, safe, and portable method commonly used to provide this information. Improvement in the quality of assessment provided by echocardiography continues to be the subject of current clinical programs…
View more
Added:
3 years ago
In this era of cost control and limited resources available to meet the growing demand for cardiovascular imaging testing, quality control initiatives that reduce the need for alternative testing are highly relevant. The implementation of continuous quality improvement (CQI) through the analysis of variations in clinical or test performance at an organizational or individual level is termed …
View more
Added:
3 years ago
The history of documented heart failure in medical literature dates back as early as the late 1700s, when William Withering recognized the therapeutic use of foxglove in patients with “dropsy”. The extract from the foxglove plant contained the cardiac glycoside digitalis, and edema – known as “dropsy” – was described in patients we now presume had the clinical syndrome of heart failure.1 Over the…
View more
A Case of Pericardial Disease Masquerading as Heart Failure with Preserved Ejection Fraction
Added:
4 months ago
Article
Added:
11 months ago
ESC-HFA 2023 - Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us onsite to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials.
This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the…
View more
Added:
10 months ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.
Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or…
View more
Added:
2 years ago
Added:
4 months ago
Added:
1 year ago
HFSA 22 - Dr James Januzzi (Massachusetts General Hospital, US) outlines the findings of the PROVE-HF study, a trial which aimed to determine the effect of sacubitril/valsartan therapy on cardiac biomarkers in patients with mitral regurgitation in heart failure with reduced ejection fraction.
Questions:
1. What was the ideology behind PROVE-HF?
2. What is the mechanism of action behind…
View more
